Haleon awarded by the Prix Vaudois des Entreprises Internationales (PVEI)
Share this article
Haleon, a former division of GSK that became independent in 2022, won the jury’s award in the “Foreign company” category.
Haelon was born in July 2022 and is the new company resulting from the spin-off of the consumer healthcare branch of the pharmaceutical laboratory Glaxosmithkline (UK). The young company holds a portfolio of world-class brands, including Voltaren, Otrivin and Panadol, some of which are produced at its Nyon-Prangins site in the canton of Vaud.
Today, no fewer than 1,100 employees of 50 different nationalities design, manufacture and market some 300 million over-the-counter products every year. Recognised as one of the most innovative and reliable companies in its field, Haleon is clearly helping to raise the profile of the Canton of Vaud and its network of expertise. The Haleon campus in Nyon/Prangins has been serving public health for more than a century, since 1917.
According to Aurélien Uldry, Haleon’s CFO and Head of the Nyon-Prangins site, ” the company benefits from a favourable ecosystem in the canton of Vaud. to supports its activities and growth ambitions. The region is home to subcontractors and suppliers of very high quality and our employees enjoy an excellent living environment on the Lake Geneva region.”
The Prix Vaudois des Entreprises Internationales (PVEI) is an awarded by the Department of the Economy, Innovation, Employment and Heritage (DEIEP), the Vaud Chamber of Commerce and Industry (CVCI) and Innovaud. In 2023, Fischer Connectors, a leader and innovator in high-performance connectivity within the Conextivity technology group, and POMOCA, a specialist in self-adhesive skin, were also rewarded.
Source: Innovaud
📸 © ARC Jean-Bernard Sieber